Table of Content


1 INTRODUCTION 32
1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION 32
1.3 MARKET SCOPE 33
1.3.1 MARKETS COVERED 33
1.3.2 YEARS CONSIDERED FOR THE STUDY 34
1.4 CURRENCY USED FOR THE STUDY 34
1.5 MAJOR MARKET STAKEHOLDERS 34
1.6 SUMMARY OF CHANGES 35

2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
FIGURE 1 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 37
2.1.1.1 Secondary sources 38
2.1.2 PRIMARY DATA 38
FIGURE 2 BREAKDOWN OF PRIMARIES: POINT-OF-CARE DIAGNOSTICS MARKET 39
2.2 MARKET ESTIMATION METHODOLOGY 39
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 40
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 40
2.2.2 END USER-BASED MARKET ESTIMATION 41
FIGURE 4 MARKET SIZE ESTIMATION: POINT-OF-CARE DIAGNOSTICS MARKET 41
2.2.3 PRIMARY RESEARCH VALIDATION 41
2.3 DATA TRIANGULATION 42
FIGURE 5 DATA TRIANGULATION METHODOLOGY 42
2.4 RESEARCH ASSUMPTIONS 43
2.5 RESEARCH LIMITATIONS 43

3 EXECUTIVE SUMMARY 44
FIGURE 6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020 VS. 2025 (USD MILLION) 44
FIGURE 7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2020 VS. 2025 (USD MILLION) 45
FIGURE 8 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2020 VS. 2025 (USD MILLION) 46
FIGURE 9 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2020 VS. 2025 (USD MILLION) 46
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE POINT-OF-CARE DIAGNOSTICS MARKET 47
?

4 PREMIUM INSIGHTS 48
4.1 POINT-OF-CARE DIAGNOSTICS MARKET OVERVIEW 48
FIGURE 11 INCREASINGLY SUPPORTIVE GOVERNMENT POLICIES AND RISING PREVALENCE OF TARGET DISEASES ARE DRIVING THE MARKET GROWTH 48
4.2 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020 49
FIGURE 12 OTC TESTING PRODUCTS DOMINATE THE POINT-OF-CARE DIAGNOSTICS MARKET IN 2020 49
4.3 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET 50
FIGURE 13 HOME CARE SETTINGS WERE THE LARGEST END-USER SEGMENT IN THE APAC POC DIAGNOSTICS MARKET IN 2020 50
4.4 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION 51
FIGURE 14 APAC TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2020–2025) 51

5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
FIGURE 15 POINT-OF-CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
5.2.1 DRIVERS 53
5.2.1.1 High prevalence of infectious diseases 53
5.2.1.2 Increasing incidence of target conditions 53
5.2.1.3 Supportive government policies 54
5.2.1.4 Dearth of skilled laboratory technicians 54
5.2.1.5 Rising number of CLIA-waived POC tests 55
TABLE 1 RECENT WAIVERS FOR MARKET PRODUCTS 55
5.2.2 RESTRAINTS 55
5.2.2.1 Pricing pressure owing to reimbursement cuts and budget constraints 55
5.2.2.2 Stringent regulatory policies 56
5.2.3 OPPORTUNITIES 56
5.2.3.1 Emerging markets 56
5.2.3.2 Healthcare decentralization 57
5.2.3.3 Increasing provider awareness about novel technologies 57
5.2.3.4 POC tests with multiplexing capabilities 58
5.2.3.5 Growing investments and funding for product development 58
5.2.4 CHALLENGES 59
5.2.4.1 Lack of alignment with definitive central lab methods 59
5.2.4.2 Inadequate adoption of POC devices in professional settings 59
5.2.4.3 Reluctance to change existing diagnostic practices 60
5.2.4.4 Premium pricing of novel platforms 60
?
5.3 TECHNOLOGY ANALYSIS: EMERGING POINT-OF-CARE APPLICATIONS 60
5.3.1 SEPSIS BIOMARKERS 60
5.3.2 STROKE/CARDIAC MARKERS 61
5.3.3 THYROID TESTING 62
5.3.4 DNA TESTING 62
5.3.5 ENDOCRINE TESTING 62
5.3.6 RESPIRATORY DIAGNOSTICS 62
5.4 GLOBAL REGULATORY LANDSCAPE 63
5.5 INDUSTRY TRENDS RELATED TO COVID-19 64
5.6 VALUE CHAIN ANALYSIS 64
FIGURE 16 VALUE CHAIN ANALYSIS?MAXIMUM VALUE ADDED DURING
THE REGULATION AND DISTRIBUTION STAGES 64
5.7 PRICING TREND ANALYSIS 65
TABLE 2 AVERAGE PRICE OF GLUCOSE MONITORING AND CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2019 (USD) 65
TABLE 3 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2019 (USD) 66
TABLE 4 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS,
BY COUNTRY, 2019 (USD) 66
5.8 ECOSYSTEM COVERAGE: PARENT MARKET (IN VITRO DIAGNOSTICS) 67
5.9 USE CASES: POINT-OF-CARE DIAGNOSTICS MARKET 68
5.9.1 REVENUE OPPORTUNITIES: IVD ASSAY DEVELOPMENT SERVICES 68
5.9.2 REVENUE OPPORTUNITIES: IVD CONTRACT RESEARCH SERVICES 69

6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT 70
6.1 INTRODUCTION 71
TABLE 5 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 71
6.2 GLUCOSE MONITORING PRODUCTS 71
TABLE 6 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 72
TABLE 7 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 72
TABLE 8 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 73
TABLE 9 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 73
TABLE 10 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 73
6.2.1 STRIPS 74
6.2.1.1 Strips make blood glucose testing easy and hassle-free 74
TABLE 11 GLUCOSE MONITORING STRIPS MARKET, BY REGION,
2018–2025 (USD MILLION) 74
6.2.2 METERS 74
6.2.2.1 Blood glucose meters are extremely helpful in the monitoring of blood glucose levels and adjusting therapeutic regimens 74
TABLE 12 GLUCOSE MONITORING METERS MARKET, BY REGION,
2018–2025 (USD MILLION) 75
6.2.3 LANCETS & LANCING DEVICES 75
6.2.3.1 Lancets & lancing devices segment to grow at the lowest CAGR in the glucose monitoring products market 75
TABLE 13 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2018–2025 (USD MILLION) 75
6.3 CARDIOMETABOLIC MONITORING PRODUCTS 76
TABLE 14 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 76
TABLE 15 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 76
TABLE 16 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE,
2018–2025 (USD MILLION) 76
TABLE 17 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 77
TABLE 18 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 77
6.3.1 CARDIAC MARKER TESTING PRODUCTS 77
6.3.1.1 Rising government initiatives for CVD research will contribute to market growth 77
TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 78
TABLE 20 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 78
TABLE 21 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 78
6.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 79
6.3.2.1 Technological advancements in blood gas/electrolyte products will drive the growth of this market segment 79
TABLE 22 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 79
TABLE 23 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 79
TABLE 24 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 80
6.3.3 HBA1C TESTING PRODUCTS 80
6.3.3.1 Government initiatives are promoting the regular use of HbA1c testing 80
TABLE 25 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 81
TABLE 26 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY END USER, 2018–2025 (USD MILLION) 81
TABLE 27 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY REGION, 2018–2025 (USD MILLION) 81
?
6.4 INFECTIOUS DISEASE TESTING PRODUCTS 82
TABLE 28 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 82
TABLE 29 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 82
TABLE 30 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 83
TABLE 31 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 83
TABLE 32 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 83
6.4.1 HIV TESTING PRODUCTS 84
6.4.1.1 Rising prevalence of HIV to drive market growth 84
TABLE 33 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 84
TABLE 34 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY END USER, 2018–2025 (USD MILLION) 84
TABLE 35 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY REGION, 2018–2025 (USD MILLION) 85
6.4.2 RESPIRATORY INFECTION TESTING PRODUCTS 85
6.4.2.1 POCT products for the diagnosis of respiratory infections offer lower sensitivity as compared to other tests 85
TABLE 36 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 86
TABLE 37 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 86
TABLE 38 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 86
6.4.3 HEPATITIS C TESTING PRODUCTS 87
6.4.3.1 Central and East Asia are among the highly affected regions with Hepatitis C 87
TABLE 39 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 87
TABLE 40 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 88
TABLE 41 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 88
6.4.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS 88
6.4.4.1 Rising prevalence of HAIs is the key factor driving market growth 88
TABLE 42 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE,
2018–2025 (USD MILLION) 89
TABLE 43 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 89
TABLE 44 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 89
6.4.5 INFLUENZA TESTING PRODUCTS 90
6.4.5.1 Rising influenza prevalence has driven the demand for influenza testing products 90
TABLE 45 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 90
TABLE 46 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 90
TABLE 47 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 91
6.4.6 TROPICAL DISEASE TESTING PRODUCTS 91
6.4.6.1 Increasing government funding for the use of POC in tropical disease testing will support market growth 91
TABLE 48 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 92
TABLE 49 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 92
TABLE 50 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 92
6.4.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS 93
6.4.7.1 Privacy and confidentiality issues are the key factors leading to the adoption of POC STD testing products 93
TABLE 51 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 93
TABLE 52 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY END USER, 2018–2025 (USD MILLION) 94
TABLE 53 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY REGION, 2018–2025 (USD MILLION) 94
6.4.8 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 94
TABLE 54 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 95
TABLE 55 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 95
TABLE 56 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 95
6.5 COAGULATION MONITORING PRODUCTS 96
TABLE 57 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 96
TABLE 58 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 97
TABLE 59 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 97
TABLE 60 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 97
TABLE 61 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 98
6.5.1 PT/INR TESTING PRODUCTS 98
6.5.1.1 PT/INR is one of the most commonly used coagulation monitoring methods 98
TABLE 62 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 98
TABLE 63 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY END USER, 2018–2025 (USD MILLION) 99
TABLE 64 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY REGION, 2018–2025 (USD MILLION) 99
6.5.2 ACT/APTT TESTING PRODUCTS 99
6.5.2.1 Rising number of patients undergoing angioplasty and dialysis globally to support market growth 99
TABLE 65 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 100
TABLE 66 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 100
TABLE 67 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 100
6.6 PREGNANCY & FERTILITY TESTING PRODUCTS 101
TABLE 68 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 101
TABLE 69 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 101
TABLE 70 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 102
TABLE 71 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 102
TABLE 72 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 102
6.6.1 PREGNANCY TESTING PRODUCTS 103
6.6.1.1 Rising inclination toward home testing to support market growth 103
TABLE 73 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 103
TABLE 74 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 103
TABLE 75 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 104
6.6.2 FERTILITY TESTING PRODUCTS 104
6.6.2.1 Increasing awareness of fertility testing to drive market growth 104
TABLE 76 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 105
TABLE 77 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 105
TABLE 78 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 105
6.7 TUMOR/CANCER MARKER TESTING PRODUCTS 106
6.7.1 INCREASING INVESTMENTS FOR RESEARCH RELATED TO POC CANCER TESTING ARE DRIVING MARKET GROWTH 106
TABLE 79 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 106
TABLE 80 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 106
TABLE 81 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 107
TABLE 82 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 107
6.8 URINALYSIS TESTING PRODUCTS 107
6.8.1 RISING PREVALENCE OF URINARY TRACT INFECTIONS IS DRIVING MARKET GROWTH 107
TABLE 83 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 108
TABLE 84 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 108
TABLE 85 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 108
TABLE 86 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 109
6.9 CHOLESTEROL TESTING PRODUCTS 109
6.9.1 RISING OBESITY LEVELS & CARDIOVASCULAR DISORDER INCIDENCE ARE THE KEY FACTORS SUPPORTING MARKET GROWTH 109
TABLE 87 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 109
TABLE 88 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 110
TABLE 89 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 110
TABLE 90 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 110
6.10 HEMATOLOGY TESTING PRODUCTS 111
6.10.1 PREFERENCE FOR LABORATORY-BASED TESTS AMONG USERS WILL IMPEDE MARKET GROWTH 111
TABLE 91 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 111
TABLE 92 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 111
TABLE 93 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 112
TABLE 94 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 112
6.11 DRUGS-OF-ABUSE TESTING PRODUCTS 112
6.11.1 RISING CONSUMPTION OF ILLICIT DRUGS HAS BOOSTED DEMAND FOR TESTING 112
TABLE 95 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 113
TABLE 96 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 113
TABLE 97 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 113
TABLE 98 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 114
6.12 FECAL OCCULT TESTING PRODUCTS 114
6.12.1 LACK OF PROPER TRAINING IN THE USE OF FECAL OCCULT TESTING
TO HAMPER MARKET ADOPTION 114
TABLE 99 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 114
TABLE 100 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 115
TABLE 101 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 115
TABLE 102 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 115
6.13 OTHER POC PRODUCTS 116
TABLE 103 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY PLATFORM, 2018–2025 (USD MILLION) 116
TABLE 104 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS,
BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 116
TABLE 105 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY END USER, 2018–2025 (USD MILLION) 117
TABLE 106 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY REGION, 2018–2025 (USD MILLION) 117